Gentian Diagnostics ASA

OB:GENT Stock Report

Market Cap: NOK 603.0m

Gentian Diagnostics Balance Sheet Health

Financial Health criteria checks 6/6

Gentian Diagnostics has a total shareholder equity of NOK205.0M and total debt of NOK0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NOK258.5M and NOK53.6M respectively. Gentian Diagnostics's EBIT is NOK25.5M making its interest coverage ratio -118.4. It has cash and short-term investments of NOK105.9M.

Key information

0%

Debt to equity ratio

NOK 0

Debt

Interest coverage ratio-118.4x
CashNOK 105.93m
EquityNOK 204.96m
Total liabilitiesNOK 53.58m
Total assetsNOK 258.54m

Recent financial health updates

Recent updates

Gentian Diagnostics ASA Just Missed Earnings - But Analysts Have Updated Their Models

Feb 14
Gentian Diagnostics ASA Just Missed Earnings - But Analysts Have Updated Their Models

Gentian Diagnostics ASA's (OB:GENT) 34% Cheaper Price Remains In Tune With Earnings

Feb 13
Gentian Diagnostics ASA's (OB:GENT) 34% Cheaper Price Remains In Tune With Earnings

With A 34% Price Drop For Gentian Diagnostics ASA (OB:GENT) You'll Still Get What You Pay For

Feb 13
With A 34% Price Drop For Gentian Diagnostics ASA (OB:GENT) You'll Still Get What You Pay For

Gentian Diagnostics' (OB:GENT) Performance Raises Some Questions

Oct 31
Gentian Diagnostics' (OB:GENT) Performance Raises Some Questions

Market Participants Recognise Gentian Diagnostics ASA's (OB:GENT) Revenues Pushing Shares 27% Higher

May 09
Market Participants Recognise Gentian Diagnostics ASA's (OB:GENT) Revenues Pushing Shares 27% Higher

Why Gentian Diagnostics' (OB:GENT) Earnings Are Weaker Than They Seem

Feb 20
Why Gentian Diagnostics' (OB:GENT) Earnings Are Weaker Than They Seem
User avatar

Launching NT-proBNP Test And Expanding Partnerships Will Broaden Cardiology Portfolio

Strategic partnerships and continual global expansion enhance Gentian's market presence and drive revenue growth.

Gentian Diagnostics ASA's (OB:GENT) P/S Is Still On The Mark Following 25% Share Price Bounce

Feb 07
Gentian Diagnostics ASA's (OB:GENT) P/S Is Still On The Mark Following 25% Share Price Bounce

Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Jun 29
Investors Appear Satisfied With Gentian Diagnostics ASA's (OB:GENT) Prospects As Shares Rocket 33%

Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Feb 14
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report

Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

Oct 28
Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation

We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

May 11
We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn

Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

Mar 20
Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?

What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Feb 21
What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?

Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

Jan 17
Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?

Financial Position Analysis

Short Term Liabilities: GENT's short term assets (NOK184.3M) exceed its short term liabilities (NOK34.1M).

Long Term Liabilities: GENT's short term assets (NOK184.3M) exceed its long term liabilities (NOK19.4M).


Debt to Equity History and Analysis

Debt Level: GENT is debt free.

Reducing Debt: GENT had no debt 5 years ago.

Debt Coverage: GENT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GENT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/15 04:39
End of Day Share Price 2026/03/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Gentian Diagnostics ASA is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MartinssonDNB Carnegie
Geir HolomDNB Carnegie